DE60220055T2 - 4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden - Google Patents

4-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)harnstoff und dessen verwendung bei der behandlung von mit glycogensynthasekinase-3 (gsk3) assoziierten leiden Download PDF

Info

Publication number
DE60220055T2
DE60220055T2 DE60220055T DE60220055T DE60220055T2 DE 60220055 T2 DE60220055 T2 DE 60220055T2 DE 60220055 T DE60220055 T DE 60220055T DE 60220055 T DE60220055 T DE 60220055T DE 60220055 T2 DE60220055 T2 DE 60220055T2
Authority
DE
Germany
Prior art keywords
disease
dementia
compound
parkinson
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60220055T
Other languages
English (en)
Other versions
DE60220055D1 (de
Inventor
Stefan Berg
Sven Hellberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SE0102440 priority Critical
Priority to SE0102440A priority patent/SE0102440D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to PCT/SE2002/001338 priority patent/WO2003004478A1/en
Publication of DE60220055D1 publication Critical patent/DE60220055D1/de
Application granted granted Critical
Publication of DE60220055T2 publication Critical patent/DE60220055T2/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links